Welcome to our dedicated page for Inovio Pharmaceu news (Ticker: INO), a resource for investors and traders seeking the latest updates and insights on Inovio Pharmaceu stock.
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) is a biotechnology company developing DNA medicines for HPV-related diseases, cancer, and infectious diseases. The INO news feed on Stock Titan aggregates company-issued press releases, regulatory updates, and other market-moving disclosures so readers can follow how INOVIO’s DNA medicine programs progress over time.
A major focus of recent INOVIO news is INO-3107, an investigational DNA medicine for adults with recurrent respiratory papillomatosis (RRP), a rare HPV-related disease of the respiratory tract. Updates include completion of a rolling Biologics License Application (BLA), FDA acceptance of the BLA for review under a Standard classification, and discussion of the accelerated approval pathway. News items also highlight clinical data showing reductions in the number of surgeries required by trial participants and long-term durability results from retrospective analyses.
Investors can also find announcements on capital-raising transactions, such as underwritten public offerings of common stock and warrants disclosed in Form 8-K filings and related press releases. INOVIO frequently reports on financial results, including quarterly earnings releases, as well as corporate governance and compensation matters like inducement stock option grants under its Inducement Plan.
Additional coverage includes scientific and clinical milestones, such as publication of Phase 1 proof-of-concept data for DNA-Encoded Monoclonal Antibody (DMAb) technology in Nature Medicine and preclinical progress in DNA-encoded protein (DPROT) programs. Conference participation and investor events are also regular topics. For followers of INO stock, this news page offers a centralized view of the company’s clinical, regulatory, financial, and strategic communications.
INOVIO (NASDAQ:INO) announced the appointment of Roger D. Dansey, M.D. to its Board of Directors, enhancing its expertise in drug development. Dr. Dansey, currently Chief Medical Officer at Seagen, has extensive experience at Merck, Gilead, and Amgen, where he led notable oncology projects. His expertise will support INOVIO's focus on its late-stage product development programs, including DNA medicines for glioblastoma and COVID-19. This strategic move aims to leverage Dr. Dansey's background to further commercialize INOVIO's innovative treatments.
INOVIO's next-generation Pan-COVID-19 vaccine candidate, INO-4802, has shown strong potential in preclinical studies, inducing robust neutralizing antibodies and T cell responses against several COVID-19 variants, including the original Wuhan strain and the B.1.1.7, B.1.351, and P.1 strains. The dual-track development approach aims to address both pandemic and endemic COVID-19 considerations. Clinical trials for INO-4802 are planned for later this year, enhancing INOVIO's strategy to provide effective cross-variant immunity.
INOVIO (NASDAQ: INO) reported its Q1 2021 financial results with total revenue of $371,000, down from $1.3 million in Q1 2020. The company posted a net loss of $54.4 million, or $0.27 per share, compared to a loss of $32.5 million, or $0.26 per share, in the previous year. INOVIO announced positive Phase 2 trial results for its COVID-19 vaccine candidate, INO-4800, demonstrating safety and immunogenicity across age groups. The company plans a global Phase 3 trial for INO-4800 and continues development of its DNA medicines for HPV-related diseases and cancer.
INOVIO (NASDAQ: INO) announced positive results from its Phase 2 clinical trial for INO-4800, its DNA vaccine candidate against COVID-19, conducted across 16 U.S. sites with approximately 400 participants. The data showed that INO-4800 was safe, well-tolerated, and immunogenic across all age groups tested, with a significant immune response observed in participants receiving a 2.0 mg dose compared to a 1.0 mg dose. INOVIO plans to submit these results to the FDA and proceed to a global Phase 3 trial, recognizing the need for effective COVID-19 vaccination.
INOVIO (NASDAQ:INO), a biotechnology company specializing in DNA medicines for infectious diseases and cancer, is scheduled to present at two virtual investor conferences in May 2021. The first is the Bank of America Merrill Lynch Health Care Conference on May 12 at 9:30 AM ET, followed by the RBC Global Healthcare Conference on May 18 at 9:45 AM ET. Both presentations will be available on INOVIO's website. INOVIO's lead candidate, VGX-3100, is the first DNA medicine to achieve efficacy endpoints in a Phase 3 trial for treating HPV-related cervical dysplasia.
INOVIO (NASDAQ: INO) will release its first quarter 2021 financial results on May 10, 2021, after market close. The company will host a live conference call and webcast at 4:30 p.m. ET to discuss these results and provide an update on its DNA Medicines Platform, including ongoing COVID-19 vaccine developments. INOVIO's VGX-3100 has achieved efficacy endpoints in a Phase 3 trial for treating precancerous cervical dysplasia, marking a significant achievement in DNA medicine.
INOVIO (NASDAQ:INO) announced it will transition to a predominantly ex-U.S. Phase 3 trial for its COVID-19 vaccine candidate, INO-4800, due to the changing landscape of COVID-19 vaccinations. The Department of Defense will discontinue funding for the Phase 3 segment of the INNOVATE trial but will continue funding the ongoing Phase 2 segment. This decision does not reflect the vaccine's data or INOVIO’s performance. INOVIO is also evaluating its pan-COVID variant vaccine, INO-4802, and remains committed to addressing pandemic and endemic vaccine needs.
INOVIO (NASDAQ: INO) has released promising results from a study on its COVID-19 vaccine candidate, INO-4800. The study indicates that INO-4800 generates a robust T cell response against all tested SARS-CoV-2 variants. Additionally, neutralizing activity against the UK and Brazilian variants is comparable to the original strain. INOVIO plans to report Phase 2 results in Q2 and move to Phase 3 shortly after. The vaccine's stability at room temperature and potential for multiple boosts highlight its significance in pandemic management.
INOVIO (NASDAQ:INO) has appointed Michael Cordera as Executive Vice President and General Counsel, effective March 15, 2021. Reporting directly to CEO Dr. J. Joseph Kim, Cordera will oversee the legal team's strategy. He brings extensive life sciences experience from his previous role at Eagle Pharmaceuticals and has held various legal positions internationally. This leadership change comes as INOVIO advances its development of DNA medicines targeting infectious diseases and cancer, with 15 clinical programs currently underway.
INOVIO (NASDAQ: INO) announced that Dr. Joseph Kim and management will present at two investor conferences in March 2021. The first is the H.C. Wainwright Global Life Sciences Conference on March 9, with virtual 1x1 meetings only. The second is the Oppenheimer 31st Annual Healthcare Conference on March 18 at 10:40 a.m. ET, featuring a corporate presentation. INOVIO is advancing DNA medicines for infectious diseases and cancer, with 15 clinical programs supported by significant partnerships.